AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05654662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Cavity Protection Dentifrice
Description: It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
Study NCT05221996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance circuit training
Study NCT05400408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOX
Description: Breath Biopsy Analysis
Study NCT05400408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VOX
Description: Breath Biopsy Analysis
Study NCT05653245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RGD Peptide
Description: adhesion molecules
Study NCT05653245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RGD Peptide
Description: adhesion molecules
Study NCT04737434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extremely low frequency electromagnetic field device
Description: with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
Study NCT04737434 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: electromagnetic field with no wave
Description: electromagnetic field with no wave
Study NCT04254692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
Study NCT04254692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
Study NCT06477003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
Study NCT06477003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature Measurement
Description: The temperature of the skin will be measured prior to and after MSOT imaging.
Study NCT05999630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial Tears Methylcellulose
Description: Participants will self-administer the artificial tears according to the schedule.
Study NCT05323604 — intervention group
Intervention type: OTHER
Intervention: Colectomy with anastomosis of any type
Description: Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
Study NCT06245005 — intervention group
Intervention type: DEVICE
Intervention: Brain exercise gameplay on a portable electronic device
Description: Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
Study NCT05362461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near Infrared Transillumination
Description: Caries imaging detection technology.
Study NCT06315972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clemastine (8 mg/day)
Description: add-on clemastine (8 mg/day) + aerobic exercise training
Study NCT06331273 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation with No-touch technique
Description: The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues.
Study NCT06315972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: add-on placebo + aerobic exercise training
Study NCT05538949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-203
Description: * Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8.
Study NCT05538949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
Study NCT06155006 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: rapid diagnostic test HCV Ab Plus Rapid test
Description: The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
Study NCT06311955 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Description: The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
Study NCT06311955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined with platinum-based regimen
Description: combined with platinum-based regimen
Study NCT05580263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
Study NCT05580263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes.
Study NCT06468891 — intervention group
Intervention type: OTHER
Intervention: Incontinence Symptom Severity Index
Description: * The ISSI consists of eight items that assess different aspects of urinary incontinence symptoms, including emptying difficulties, nocturia, daytime frequency, stress incontinence, urge incontinence, leakage with activity, and pad use.~* Each item is scored on a scale of (0 to 3) or (0 to 4), depending on the severity of the symptom. Higher scores indicate more severe symptoms.~* The total ISSI score is obtained by summing the scores of all eight items, resulting in a range of 0 to 32 or 0 to 40, depending on the version used.~* The severity of urinary incontinence symptoms can be categorized based on the total ISSI score
Study NCT06468891 — intervention group
Intervention type: OTHER
Intervention: Force platform
Description: Use the provided software or tools to analyze the recorded force data, including Step Cycle Duration (ms), Time of Contact (ms), Swing Duration (ms), Single Step Duration (ms), Double Support Duration (ms), Initial Contact (ms) , Loading Response (ms), Mid Stance (ms), Terminal Stance (ms), Step Cycle Length, Half Step Length for left and right lower limbs.~* Interpret the data to draw conclusions about the forces exerted during the subject's movements or activities.
Study NCT06468891 — intervention group
Intervention type: OTHER
Intervention: The STT three-dimensional motion analysis (3DMA) system
Description: The STT three-dimensional motion analysis (3DMA) system (STT Systems Company, Zuatzu Business Park, Easo Building, 2nd Floor, San Sebastián, Spain) was used for the assessment of spatiotemporal characteristics of gait. It is an indoor optical system that consists of four cameras, fifteen markers, and computer software for automatic three-dimensional motion capture and analysis. CLINICAL 3DMA V.6.11 is professional software with highly accurate marker tracking. The STT Helen Hayes protocol was used for the gait analysis in this study.
Study NCT05887713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Alpha-Stim 100
Description: Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
Study NCT05887713 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
Study NCT06408077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaCl-Administration
Description: Intravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
Study NCT06014853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOL-804-F
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
Study NCT06014853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zytiga
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
Study NCT05291546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN9035
Description: Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
Study NCT04770324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interposition supraciliary implant
Description: Surgical placement of 2 interposition supraciliary implant in the supraciliary space
Study NCT05326789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA catheter
Description: balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
Study NCT05283408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Study NCT05283408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration dexmedetomidine and low-dose esketamine infusion
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Study NCT05283408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration dexmedetomidine and high-dose esketamine infusion
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Study NCT04762238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
Study NCT04762238 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
Study NCT05538494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR intervention
Description: Training is applied to this group using low-load exercises with restriction of blood flow. Based on the variables used by the major part of the protocols used in studies on the ERFS, the protocol that will be applied to this group will consist of the following parameters.~* Training: 1 series of 30 repetitions followed by 3 series of 15 repetitions of squats~* Rest between series: Duration of 45 seconds.~* Workload: 30% of 1RM.~* Cadence: 2 seconds for the concentric phase and 2 seconds for the eccentric phase (2:2).~* Cuff pressure: The inflation pressure will be individualized for each individual.~A pressure equivalent to 80% of the minimum pressure necessary for the total occlusion of the femoral artery.~• Cuff placement: proximal quadriceps.
Study NCT05538494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High load intervention
Description: A program will be applied to this group of exercise with high loads as a method of treatment in which the following will be applied parameters:~* Training: 4 series of 12 repetitions of squats.~* Rest between series: Duration 2 minutes.~* Workload: 70% of 1RM.
Study NCT05374642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: tablet-based cognitive training for 12 weeks, 30 minutes each time, at least 5 times a week
Study NCT05374642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control
Description: tablet-based cognitive training tasks with weak or no difficulty changes, 5 times a week, 30 minutes each time for 12 weeks
Study NCT05443464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OSSM-001
Description: Direct IV infusion of OSSM-001
Study NCT05658458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
Study NCT05291546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Part B: Selected doses administered by IV infusion on day 1.
Study NCT05291546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
Study NCT05910203 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The effectiveness of education
Description: Training will be provided on smoking cessation.
Study NCT05211674 — intervention group
Intervention type: OTHER
Intervention: quantified analysis of postural control during activities of daily living
Description: functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
Study NCT06547333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection
Study NCT06547333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06406582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia laminate veneer
Description: Zirconia veneers are milled with computer-aided manufacturing technology from multilayered zirconia discs with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with a hydrofluoric acid-nitric acid mixture. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
Study NCT06406582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Disilicate laminate veneer
Description: Lithium Disilicate veneers are milled with computer-aided manufacturing technology from lithium disilicate blocks with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with hydrofluoric acid. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
Study NCT05547919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-PSMA PET/CT
Description: Patients with metastasized gastrointestinal tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
Study NCT05117684 — intervention group
Intervention type: PROCEDURE
Intervention: Novel
Description: Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
Study NCT05117684 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional
Description: Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
Study NCT03981640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
Study NCT03981640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
Study NCT03981640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental stress test
Description: Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
Study NCT06131983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-DUX4 for Injection
Description: single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
Study NCT06131983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by IV infusion
Study NCT05199233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse S™ Headband system
Description: Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
Study NCT04644276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mask with Mask Adhesive/Arm 1
Description: Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
Study NCT04644276 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mask without Mask Adhesive / Arm 2
Description: Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
Study NCT04727450 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
Study NCT04727450 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical training
Description: Involves learning of preselected routines of line dancing taught by a line dance instructor.